Clinical trials
for patients
Learn about available clinical trials
-
June 23, 2025Pamplona/MadridIn recruitment
MCLA-129-CL01 Clinical trial of MCLA-129 in patients with advanced NSCLC and other solid tumors
The aim of this study is to find out the possible side effects of the study drug, whether the study drug can stop the growth or spread of cancer cells in your body, how your body processes the study drug, and how certain biomarkers or small substances in your body change in response to the study drug. -
June 23, 2025Pamplona/MadridIn recruitmentEarly phase
RAY902CT Unmasked assay of RAY21 to inhibit the classical complement pathway in immunological diseases
The main objective is to evaluate the safety and tolerability of multiple s.c. administrations of RAY121 in patients with complement immunodeficiencies -
June 17, 2025Pamplona/MadridIn recruitment
20210181 Phase 3, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy, safety and tolerability of maridebart cafraglutide in adult participants without type 2 diabetes mellitus who are obese or overweight.
This study is being conducted to test whether maridebart cafraglutide [MariTide (formerly AMG 133)] is a safe drug, can reduce body weight, and can improve weight-related conditions in people like you who are living with obesity or being overweight, but do not have type 2 diabetes (T2DM, a disease that occurs when blood sugar levels are too high). -
June 16, 2025PamplonaIn recruitmentEarly phase
MPSA-153-002 EC in combination of NMS-01940153E and atezolizumab with or without prior low-dose decitabine for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors.
The aim of this study is to learn about the safety, tolerability and antitumor properties of NMS-01940153E administered with atezolizumab and with or without decitabine for the treatment of hepatocellular carcinoma (HCC). -
June 16, 2025Pamplona/MadridIn recruitment
CP-START-001 Phase I/II human clinical trial of STAR0602 in patients with inoperable, locally advanced or metastatic antigen-rich inoperable solid tumors.
The main objective is to evaluate the safety/tolerability and toxicity of STAR0602 and to determine the recommended dose for Phase 2 (RP2D) of STAR0602. -
June 11, 2025PamplonaIn recruitmentEarly phase
64042056ALZ2001 Trial of JNJ-64042056, an active immunotherapy directed against phosphorylated tau in participants with preclinical Alzheimer's disease.
The purpose of this study is to evaluate the safety and efficacy of JNJ-64042056 in slowing the progression of Alzheimer's disease (AD) in individuals with preclinical AD. Having preclinical Alzheimer's disease means being in an early stage of the disease in which signs of memory problems are not yet apparent. At this stage, elevated levels of abnormal proteins (amyloid and tau) may be detected in the blood, cerebrospinal fluid or on a PET scan. -
June 6, 2025MadridIn recruitment
MK-5909-003 Phase 1b/2 clinical trial to evaluate safety and efficacy of raludotatug deruxtecan, with or without other drugs in participants with high-grade serous epithelial ovarian carcinoma, primary peritoneal carcinoma or tubal carcinoma.
The main objective is to evaluate the safety and tolerability of raludotatug deruxtecan (R-DXd) administered in combination with carboplatin in participants with recurrent high-grade ovarian carcinoma. -
May 28, 2025Pamplona/MadridIn recruitment
20230005 Randomized, open-label, multicenter clinical trial of xaluritamig vs. cabazitaxel or a second androgen receptor-targeted therapy in subjects with metastatic castration-resistant prostate cancer.
This study is being conducted to learn more about the safety and efficacy of xaluritamig compared to already approved standard treatments in patients with prostate cancer that has spread to other parts of the body (also called metastatic castration-resistant prostate cancer [mCRPC]) who have already been treated with chemotherapy. -
May 28, 2025Pamplona/MadridIn recruitment
D7080C00001 Trial to evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of AZD0022 in monotherapy and in combination with antineoplastic agents in patients with tumors carrying a KRASG12D mutation (ALAFOSS-01).
The objective of the research trial is to obtain more information about AZD0022 and also to better understand the disease being studied and the associated health problems. -
May 27, 2025PamplonaIn recruitmentEarly phase
1456-0001 Study to evaluate different doses of BI 1831169 alone and in combination with ezabenlimab in people with different types of advanced cancer (solid tumors).
The aim of the study is to find out the highest amount of BI 1831169 that can be administered without too many side effects, both alone and in combination with another drug (ezabenlimab), as well as to observe the effect it may have on cancerous tumors and on the body.